Adverum Biotechnologies Stock Forecast, Price & News

+0.04 (+1.10 %)
(As of 06/23/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.17 million shs
Average Volume1.92 million shs
Market Capitalization$358.44 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ADVM News and Ratings via Email

Sign-up to receive the latest news and ratings for Adverum Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

Adverum Biotechnologies logo

About Adverum Biotechnologies

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal diseases, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.07 out of 5 stars

Medical Sector

59th out of 2,105 stocks

Biological Products, Except Diagnostic Industry

8th out of 198 stocks

Analyst Opinion: 4.1Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Adverum Biotechnologies (NASDAQ:ADVM) Frequently Asked Questions

Is Adverum Biotechnologies a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adverum Biotechnologies in the last twelve months. There are currently 8 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Adverum Biotechnologies stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADVM, but not buy additional shares or sell existing shares.
View analyst ratings for Adverum Biotechnologies
or view top-rated stocks.

What stocks does MarketBeat like better than Adverum Biotechnologies?

Wall Street analysts have given Adverum Biotechnologies a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Adverum Biotechnologies wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Adverum Biotechnologies' next earnings date?

Adverum Biotechnologies is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Adverum Biotechnologies

How were Adverum Biotechnologies' earnings last quarter?

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) released its earnings results on Wednesday, May, 5th. The biotechnology company reported ($0.29) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.38) by $0.09. The biotechnology company earned $7.50 million during the quarter, compared to analysts' expectations of $0.46 million.
View Adverum Biotechnologies' earnings history

How has Adverum Biotechnologies' stock price been impacted by COVID-19 (Coronavirus)?

Adverum Biotechnologies' stock was trading at $9.26 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ADVM stock has decreased by 60.5% and is now trading at $3.66.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ADVM?

10 brokers have issued twelve-month price objectives for Adverum Biotechnologies' stock. Their forecasts range from $5.00 to $36.00. On average, they anticipate Adverum Biotechnologies' stock price to reach $14.13 in the next twelve months. This suggests a possible upside of 285.9% from the stock's current price.
View analysts' price targets for Adverum Biotechnologies
or view top-rated stocks among Wall Street analysts.

Who are Adverum Biotechnologies' key executives?

Adverum Biotechnologies' management team includes the following people:
  • Dr. Laurent Fischer, CEO & Director (Age 57, Pay $922.92k)
  • Ms. Leone D. Patterson M.B.A., Pres, CFO, Principal Financial Officer & Principal Accounting Officer (Age 58, Pay $914.55k)
  • Ms. Angela Thedinga M.B.A., M.P.H., Chief Technology Officer (Age 39, Pay $577.96k)
  • Dr. Aaron Osborne MBBS, Consultant (Age 46, Pay $682.4k)
  • Ms. Myesha Lacy, VP of Investor Relations & Corp. Communications
  • Mr. Peter Soparkar J.D., Chief Legal Officer & Corp. Sec. (Age 50)
  • Ms. Dena House, VP of HR
  • Mr. Christopher J. DeRespino, Chief Bus. Officer
  • Ms. Julie Clark M.D., Acting Chief Medical Officer

What is Laurent Fischer, M.D.'s approval rating as Adverum Biotechnologies' CEO?

3 employees have rated Adverum Biotechnologies CEO Laurent Fischer, M.D. on Laurent Fischer, M.D. has an approval rating of 72% among Adverum Biotechnologies' employees.

Who are some of Adverum Biotechnologies' key competitors?

What other stocks do shareholders of Adverum Biotechnologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adverum Biotechnologies investors own include CTI BioPharma (CTIC), California Resources (CRC), CA (CA), BlackRock (BLK), Amarin (AMRN), Endologix (ELGX), Immunomedics (IMMU), Advanced Micro Devices (AMD), Aurinia Pharmaceuticals (AUPH) and Genocea Biosciences (GNCA).

What is Adverum Biotechnologies' stock symbol?

Adverum Biotechnologies trades on the NASDAQ under the ticker symbol "ADVM."

Who are Adverum Biotechnologies' major shareholders?

Adverum Biotechnologies' stock is owned by a number of retail and institutional investors. Top institutional investors include RA Capital Management L.P. (9.56%), RTW Investments LP (7.50%), BlackRock Inc. (7.38%), Versant Venture Management LLC (5.18%), UBS Group AG (3.37%) and JPMorgan Chase & Co. (2.02%). Company insiders that own Adverum Biotechnologies stock include James Paul Scopa, Laurent Fischer, Leone D Patterson, Mehdi Gasmi, Patrick Machado and Peter Soparkar.
View institutional ownership trends for Adverum Biotechnologies

Which major investors are selling Adverum Biotechnologies stock?

ADVM stock was sold by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Dimensional Fund Advisors LP, WS Management Lllp, RA Capital Management L.P., Barclays PLC, Stenahm Asset Managment Ltd, Man Group plc, and Northern Trust Corp. Company insiders that have sold Adverum Biotechnologies company stock in the last year include Leone D Patterson, and Mehdi Gasmi.
View insider buying and selling activity for Adverum Biotechnologies
or view top insider-selling stocks.

Which major investors are buying Adverum Biotechnologies stock?

ADVM stock was purchased by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., UBS Group AG, Rafferty Asset Management LLC, Citigroup Inc., BlackRock Inc., Geode Capital Management LLC, Renaissance Technologies LLC, and RTW Investments LP. Company insiders that have bought Adverum Biotechnologies stock in the last two years include James Paul Scopa, Laurent Fischer, Patrick Machado, and Peter Soparkar.
View insider buying and selling activity for Adverum Biotechnologies
or or view top insider-buying stocks.

How do I buy shares of Adverum Biotechnologies?

Shares of ADVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adverum Biotechnologies' stock price today?

One share of ADVM stock can currently be purchased for approximately $3.66.

How much money does Adverum Biotechnologies make?

Adverum Biotechnologies has a market capitalization of $358.44 million and generates $250,000.00 in revenue each year. The biotechnology company earns $-117,510,000.00 in net income (profit) each year or ($1.38) on an earnings per share basis.

How many employees does Adverum Biotechnologies have?

Adverum Biotechnologies employs 167 workers across the globe.

What is Adverum Biotechnologies' official website?

The official website for Adverum Biotechnologies is

Where are Adverum Biotechnologies' headquarters?

Adverum Biotechnologies is headquartered at 800 Saginaw Drive, Redwood City CA, 94063.

How can I contact Adverum Biotechnologies?

Adverum Biotechnologies' mailing address is 800 Saginaw Drive, Redwood City CA, 94063. The biotechnology company can be reached via phone at 650-656-9323 or via email at [email protected]

This page was last updated on 6/24/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.